Advancing obesity drug discovery: Cell-based assays for GLP-1 and the G-Suite
Supported by:
19 March 2025
3:00pm
Shares
- Like
- Digg
- Del
- Tumblr
- VKontakte
- Buffer
- Love This
- Odnoklassniki
- Meneame
- Blogger
- Amazon
- Yahoo Mail
- Gmail
- AOL
- Newsvine
- HackerNews
- Evernote
- MySpace
- Mail.ru
- Viadeo
- Line
- Comments
- Yummly
- SMS
- Viber
- Telegram
- Subscribe
- Skype
- Facebook Messenger
- Kakao
- LiveJournal
- Yammer
- Edgar
- Fintel
- Mix
- Instapaper
- Copy Link
Register now to gain valuable insights into the latest advancements in obesity drug discovery and enhance your research capabilities.
The field of obesity therapeutics is advancing rapidly, driven by breakthroughs like semaglutide and tirzepatide. These innovations have led to the development of next-generation treatments targeting key GPCRs, including GLP-1, GIP, and glucagon receptors, offering the potential for significant weight loss and metabolic improvements.
This webinar will explore the challenges and opportunities in obesity drug discovery, highlighting a range of well-characterised assay solutions that have supported over 100 obesity therapeutic programmes worldwide.
Join Dr Frances Reichert, Technical Specialist for Biologics at Eurofins BioPharma Product Testing, and Shruti Kumar, Field Application Scientist at Eurofins DiscoverX, as they present a robust portfolio of pre-qualified functional assays for measuring cAMP, β-arrestin, and receptor internalisation, enabling effective screening and characterisation of therapeutic candidates targeting obesity-related GPCRs.
Key highlights:
- Advanced assays: Discover cutting-edge screening and functional assays for GLP-1, GIP, glucagon, and other GPCR receptors, accelerating obesity therapeutic discovery.
- Drug development landscape: Understand the latest trends in obesity drug development, including single, dual, and triple agonist approaches.
- High-quality data: Learn how robust in vitro pharmacology assays provide reliable data to optimise compound efficacy and safety.
- Real-world insights: Gain insights from real-world data demonstrating the utility of these tools for receptor-specific profiling.
- Automation and efficiency: Explore the benefits of integrating automation into cell-based assays for improved efficiency and scalability in obesity research.
Register now and discover the latest breakthroughs in obesity drug discovery!
Shruti Kumar, M.S. – Field Application Scientist, Eurofins DiscoverX Shruti Kumar holds a master’s degree in pharmacology from Campbell University, North Carolina, specialising in bioassay development and validation. With over a decade of experience in cell-based assay development, she has built expertise in working with complex biologics and biosimilars. As a field application scientist at Eurofins DiscoverX, Kumar provides technical expertise, training, and collaborative solutions across the Asia-Pacific region, working closely with researchers and biopharma clients. She supports the adoption and integration of Eurofins DiscoverX’s cell-based assays, ensuring their seamless implementation in clinical development programs for therapeutics. Dr Frances Reichert – Technical Specialist for Biologics, Eurofins BioPharma Product Testing, Planegg/Munich, Germany Dr. Frances Reichert holds a Ph.D. from the University of Frankfurt and studied at the University of Applied Sciences in Bingen am Rhein, where she gained hands-on experience in antibody manufacturing and related areas. Reichert has been employed at Eurofins BPT Munich (DACH) since 2010 and is currently a technical specialist for biologics within the sales department, filling the gap between technical requirements and customer needs. Reichert has accumulated more than 10 years of experience in the development and validation of cell-based potency assays and binding ELISAs. Prior to this role, she served as Head of the Bioassay Development and Validation Department at Eurofins BPT Munich. Since 2010, she has worked as a quality control manager for QC bioassays. From 2016 onwards, she led a small team as group leader within the bioassay department, focusing on the development, qualification, validation, and transfer of various potency assays. Is the webinar free? When will the webinar take place? I’m busy. Can I watch it later? What are the benefits of attending live? How long will the webinar be? What do I need to watch this webinar? Do I receive a certificate?OUR SPEAKERS
FAQs
Yes – there is no charge to watch the webinar, either live or on-demand.
The webinar will take place live on 19 March 2025 at 3PM GMT.
The webinar will become available to watch on-demand shortly after the live webinar takes place.
During the live webinar, you’ll be able to ask the speakers your questions, which will then be answered during the live Q&A session towards the end of the webinar.
This webinar will last for up to one hour.
All you need is a computer with an internet connection. Be sure to use headphones if in an office environment.
Yes, you will receive a certificate if you attend the webinar live. The certificate will be sent with your on-demand video link.